Summary
We have developed a simple sensitive fluorometric assay for the measurement of total Bisantrene in plasma, red blood cells, and tissues to facilitate preclinical and clinical pharmacologic assessment of this active anticancer agent. The assay was used to measure the plasma disappearance and tissue concentrations of Bisantrene in the rabbit. Results are comparable to those reported with HPLC assays and with measurement of radioactivity in combusted tissue following IV administration of radiolabeled Bisantrene. We demonstrated that when a plasma concentration of approximately 50 μg/ml is not exceeded, Bisantrene remains in solution at that concentration. If Bisantrene is introduced into plasma at a concentration exceeding 50 μg/ml, precipitation of the drug is initiated and continues until the plasma concentration is no greater than 15 μg/ml. This finding supports our previous recommendation that in clinical trials Bisantrene should be administered at low concentrations over prolonged periods of time to maximize the bioavailability of the drug by minimizing precipitation of the drug in plasma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bachur NR, Moore AL, Bernstein JG, Liu A (1970) Tissue distribution and disposition of daunomycin (NSC-82151) in mice, fluorometric and isotopic methods. Cancer Chemother Rep 54:89–94
Holford NHG (1982) DRUGMODEL in Supplement 1, Public Procedures Notebook (H. M. Perry, ed), Bold Beranek and Newman Inc., Cambridge, MA
Kvols LK, Powis G, Kovach JS (1983) Bisantrene: Reduced toxicity with administration of low concentrations by continuous 72-hour intravenous infusion. (Abstract), Proceedings of 13th International Congress of Chemotherapy, Symposium on Bisantrene, pp 23–27
Myers JM, Von Hoff DD, Kuhn JG (1983) Bisantrene associated anaphylactoid reactions and potential efficacy of prophylactic measures. (Abstract), Proceedings of 13th International Congress of Chemotherapy, Symposium on Bisantrene, pp 18–22
National Cancer Institute (1979) Investigator's brochure (L216,942,9,10-Anthraceredicarboxaldehyde bis[(4,5-dehydro-1H-imidazole-2-yl)hydrazone]-dihydrochloride. Prepared by Medical Research Division, American Cyanamid Company, Pearl River, NY for Co-Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute. NCI, Bethesda
Peng YM, Davis TP, Alberts DS (1981) High performance liquid chromatography of a new anticancer drug, ADCA — Physiochemical properties and pharmacokinetics. Life Sci 29:361–369
Peng YM, Ormberg D, Alberts DS (1982) Improved high-performance liquid chromatography of the new antineoplastic agents Bisantrene and mitoxantrone. J Chromatogr 233:235–247
Powis G (1981) Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenediacarboxaldehyde bis (4,5-dihydro-1H-imidazole-2-yl hydrazone) dihydrochloride. J Chromatogr, 226:514–520
Powis G, Kovach JS (1983) Disposition of Bisantrene in humans and rabbits: Evidende for intravascular deposition of the drug as a cause of phlebitis. Cancer Res, 43:925–929
Wu WH, Nicolau G (1982) Disposition and metabolic profile of a new antitumor agent: CL 216,942 (Bisantrene) in laboratory animals. Cancer Treat Rep 66:1173–1185
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Buck, M., Kovach, J.S. Blood and tissue concentrations of Bisantrene measured by a simple fluorometric assay. Cancer Chemother. Pharmacol. 15, 40–43 (1985). https://doi.org/10.1007/BF00257292
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257292